Baxter opens r&d facility in Alliance Park, Belgium
Provides 15,500sq m of office and laboratory space
Baxter has moved its r&d facility, including commercial and administrative offices, to Parc de l'Alliance (Alliance Park), Braine l'Alleud, near Brussels, Belgium. One of three r&d facilities in Europe, Alliance Park represents a major milestone for Baxter operations in Belgium, and strengthens the company's capacity to develop leading-edge technologies and products.
The facility merges two organisations located previously in Brussels and Nivelles and houses 430 employees.
Baxter says the location is unique in that its activities cover all stages of a product's lifecycle from conception to registration. In this facility, the firm says it will further increase efficiency in the early phases of bringing new therapies to the market.
‘Baxter has a rich history in Belgium having opened the first offices outside the US in 1954 and the first plant in Lessines in 1970. Alliance Park provides a critical step forward in Baxter's future by aligning multiple functions in one area, thereby encouraging more ideas to develop into solutions,’ said Baxter corporate vp and president, International Ludwig Hantson.
Alliance Park will provide Baxter Europe, Middle East and Africa (EMEA) with an r&d infrastructure that will meet upcoming demands for product development and registration. To remain competitive with leading technological innovation, Baxter Alliance Park teams will conduct joint research with leading European research universities and organisations in Belgium, as well as in Lille and Paris, France.
Researchers at Baxter Alliance Park concentrate on the development of new technologies and projects, including solutions for Peritoneal Dialysis, recombinant and plasma-based therapeutics, vaccines, initiatives in regenerative medicine, parenteral nutrition, and enhanced packaging systems for the company's Medication Delivery and BioScience global business units.
